Physician profile
Peter V Mitrev
NPI 1902859374
$3,430.30
in general payments reported to CMS, 2019-2025
23 companies · $463 in 2025
The $463 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $354 · 2021: $650 · 2022: $311 · 2023: $552 · 2024: $367 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $634.89 | 2019-2025 | Voyager Dslt, Rocklatan, Clareon |
| Abbvie INC. | $513.94 | 2023-2025 | |
| Allergan, INC. | $428.78 | 2019-2022 | |
| Ocular Therapeutix, INC. | $355.26 | 2020-2023 | Dextenza |
| Mallinckrodt Hospital Products INC. | $339.63 | 2021-2024 | Acthar |
| Aerie Pharmaceuticals, INC. | $264.52 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $253.60 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $94.65 | 2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Sun Pharmaceutical Industries INC. | $68.41 | 2022-2023 | Cequa |
| Bausch & Lomb Americas INC. | $67.67 | 2023-2024 | Vyzulta, Prolensa, Xiidra |
| Tarsus Pharmaceuticals, INC. | $54.43 | 2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $49.36 | 2021-2022 | |
| Lensar, INC. | $45.16 | 2025 | Lensar Laser System |
| Novartis Pharmaceuticals Corporation | $44.26 | 2020-2021 | |
| Dompe US, INC. | $42.39 | 2020-2025 | Oxervate |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $30.74 | 2023 | Tyrvaya |
| Sight Sciences, INC. | $24.93 | 2021 | |
| Biotissue Holdings INC. | $23.53 | 2024 | |
| Thea Pharma INC. | $22.50 | 2025 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $19.97 | 2019 | |
| Omeros Corporation | $19.62 | 2019 | |
| Glaukos Corporation | $16.71 | 2022 | |
| Ani Pharmaceuticals, INC. | $15.35 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mitrev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.